Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer (2023)
Gardani, Carla Fernanda Furtado; Pedrazza, Eduardo Luiz; Paz, Victória Santos; Zanirati, Gabriele Goulart; Costa, Jaderson Costa da; Andrejew, Roberta 
; Ulrich, Henning ; Scholl, Juliete Nathali ; Figueiró, Fabrício ; Rockenbach, Liliana ; Morrone, Fernanda Bueno
Fonte: Pharmaceuticals. Unidade: IQ
Assuntos: NEOPLASIAS PROSTÁTICAS, CITOMETRIA DE FLUXO, HIDRÓLISE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GARDANI, Carla Fernanda Furtado et al. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer. Pharmaceuticals, v. 16, p. 1-17 art. 1619, 2023Tradução . . Disponível em: https://dx.doi.org/10.3390/ph16111619. Acesso em: 19 maio 2024.APA
Gardani, C. F. F., Pedrazza, E. L., Paz, V. S., Zanirati, G. G., Costa, J. C. da, Andrejew, R., et al. (2023). Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer. Pharmaceuticals, 16, 1-17 art. 1619. doi:10.3390/ph16111619NLM
Gardani CFF, Pedrazza EL, Paz VS, Zanirati GG, Costa JC da, Andrejew R, Ulrich H, Scholl JN, Figueiró F, Rockenbach L, Morrone FB. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer [Internet]. Pharmaceuticals. 2023 ; 16 1-17 art. 1619.[citado 2024 maio 19 ] Available from: https://dx.doi.org/10.3390/ph16111619Vancouver
Gardani CFF, Pedrazza EL, Paz VS, Zanirati GG, Costa JC da, Andrejew R, Ulrich H, Scholl JN, Figueiró F, Rockenbach L, Morrone FB. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer [Internet]. Pharmaceuticals. 2023 ; 16 1-17 art. 1619.[citado 2024 maio 19 ] Available from: https://dx.doi.org/10.3390/ph16111619
